Longer-term follow-up data for Study 1540: Safety profile1

Adverse reactions in ≥10% of patients with mCSCC or laCSCC who were not candidates for curative surgery or curative radiation and who received LIBTAYO in Study 15401

Chart, longer-term follow-up data in clinical study 1540: mCSCC or laCSCC (N=193)
  • Grade ≥3 adverse reactions occurred in 94 patients (48.7%). The most common Grade ≥3 adverse reactions were hypertension (n=9, 4.7%) and anemia and cellulitis (each n=8, 4.1%)1
  • *Adverse reactions reported in ≥10% of patients, ordered by frequency of any grade.1
  • Adapted with permission from Rischin et al, 2020.1
  • CSCC=cutaneous squamous cell carcinoma; laCSCC=locally advanced CSCC; mCSCC=metastatic CSCC.

Reference: 1. Rischin D, Khushalani NI, Schmults CD, et al. Phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): longer follow-up. Poster presented at: American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program; May 29-31, 2020.